The patent, titled “Methods for Treating Eye Conditions,” broadly states the technology can be used to treat eye conditions such as glaucoma, cataracts and presbyopia.
BIOLASE has a presence in the ophthalmology market with its wholly owned subsidiary OCCULASE.
More Articles on Ophthalmology:
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
Valeant Acquires Bausch + Lomb for $8.7B
